v3.26.1
CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($)
$ in Thousands
Total
Conversion of redeemable convertible preferred stock to common stock upon initial public offering
Conversion of SAFEs upon initial public offering
Conversion of convertible notes upon initial public offering
Common Stock
Common Stock
Conversion of redeemable convertible preferred stock to common stock upon initial public offering
Common Stock
Conversion of SAFEs upon initial public offering
Common Stock
Conversion of convertible notes upon initial public offering
Additional paid-in capital
Additional paid-in capital
Conversion of redeemable convertible preferred stock to common stock upon initial public offering
Additional paid-in capital
Conversion of SAFEs upon initial public offering
Additional paid-in capital
Conversion of convertible notes upon initial public offering
Accumulated deficit
Accumulated other comprehensive income (loss)
Beginning balance (in shares) at Jan. 31, 2023 146,360,207                          
Beginning balance at Jan. 31, 2023 $ 1,301,121                          
Ending balance at Jan. 31, 2024 $ 1,301,121                          
Ending balance (in shares) at Jan. 31, 2024 146,360,207                          
Beginning balance (in shares) at Jan. 31, 2023 [1]         44,295,279                  
Beginning balance at Jan. 31, 2023 $ (840,723)       $ 1 [1]       $ 298,663       $ (1,104,483) $ (34,904)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Net loss (331,552)                       (331,552)  
Other comprehensive income (loss), net of tax 6,611                         6,611
Issuance of common stock upon exercise of stock options (in shares) [1]         821,729                  
Issuance of common stock upon exercise of stock options 6,400               6,400          
Vesting of early exercised stock options 312               312          
Stock-based compensation 76,981               76,981          
Ending balance (in shares) at Jan. 31, 2024 [1]         45,117,008                  
Ending balance at Jan. 31, 2024 (1,081,971)       $ 1 [1]       382,356       (1,436,035) (28,293)
Ending balance at Jan. 31, 2025 $ 1,301,121                          
Ending balance (in shares) at Jan. 31, 2025 146,360,207                          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Net loss $ (181,078)                       (181,078)  
Other comprehensive income (loss), net of tax (9,329)                         (9,329)
Issuance of common stock upon exercise of stock options (in shares) [1]         665,863                  
Issuance of common stock upon exercise of stock options 4,521               4,521          
Vesting of early exercised stock options 1,658               1,658          
Stock-based compensation $ 79,300               79,300          
Ending balance (in shares) at Jan. 31, 2025 45,782,871       45,782,871 [1]                  
Ending balance at Jan. 31, 2025 $ (1,186,899)       $ 1 [1]       467,835       (1,617,113) (37,622)
Increase (Decrease) in Temporary Equity [Roll Forward]                            
Conversion of redeemable convertible preferred stock to common stock upon initial public offering (in shares) (146,360,207)                          
Conversion of redeemable convertible preferred stock to common stock upon initial public offering $ (1,301,121)                          
Ending balance at Jan. 31, 2026 $ 0                          
Ending balance (in shares) at Jan. 31, 2026 0                          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Net loss $ (398,030)                       (398,030)  
Other comprehensive income (loss), net of tax 34,397                         34,397
Issuance of common stock upon initial public offering, net of underwriting costs (in shares) [1]         30,000,000                  
Issuance of common stock upon initial public offering, net of underwriting costs 713,302               713,302          
Deferred offering costs (9,290)               (9,290)          
Stock issued during period, shares, conversion of convertible securities (in shares) [1]         1,742,352 146,599,125 7,851,008 12,827,963            
Stock issued during period, shares, conversion of convertible securities 110 $ 1,301,121 $ 196,275 $ 320,699   $ 1 [1]     110 $ 1,301,120 $ 196,275 $ 320,699    
Reclassification of preferred stock warrants & SAFE warrants to equity 31,343               31,343          
Issuance of equity-classified warrants in connection with term loan $ (11,007)               (11,007)          
Issuance of common stock upon exercise of stock options (in shares) 3,002,251       3,002,251 [1]                  
Issuance of common stock upon exercise of stock options $ 23,846               23,846          
Issuance of common stock upon settlement of restricted stock units, net of shares withheld (in shares) [1]         1,369,936                  
Issuance of common stock upon settlement of restricted stock units, net of shares withheld (17,760)               (17,760)          
Vesting of early exercised stock options 918               918          
Early exercised shares repurchased (in shares) [1]         (729)                  
Stock-based compensation 187,022               187,022          
Ending balance (in shares) at Jan. 31, 2026 [1]         249,174,777                  
Ending balance at Jan. 31, 2026 $ 1,208,061       $ 2 [1]       $ 3,226,427       $ (2,015,143) $ (3,225)
[1] The share amounts listed above combine common stock, Class A common stock and Class B common stock. In connection with the completion of our initial public offering, all previously outstanding shares of common stock were reclassified into Class A common stock and Class B common stock. Refer to Note 1 for more information.